Fractyl Health today announced that it published two-year durability data from its Revita-1 clinical study in Europe and South America.
Lexington, Massachusetts-based Fractyl’s trial included two-year follow-up from 34 type 2 diabetes patients who received the company’s Revita duodenal mucosal resurfacing (DMR) procedure.
Get the full story at our sister site, Drug Delivery Business News.